Strategy

K2 Therapeutics CEO Ying Huang discusses the three priorities that define a successful biotech: unmet need, development cost, and accessible pricing.

K2 Therapeutics CEO Ying Huang on the drug development pipeline — and the compounding attrition rates that make FDA approval the exception.

How drug pricing, tariffs, and manufacturing decisions are becoming connected.

A changing of the guard atop Pharm Exec’s latest listing of the top biopharma Rx revenue producers reflects an industry being remade in real time, becoming as much a map of franchise quality and market momentum as it is the strategic shifts and bets necessary to turn today’s disruption into tomorrow’s growth.

As trust shifts from a stated value to an operating condition, pharmaceutical leaders face new expectations for how credibility is built, governed and sustained under continuous scrutiny.

Q&A with PwC’s Glenn Hunzinger explores why biopharma M&A investment could approach $300 billion in 2026, how drugmakers are balancing risk amid patent cliffs and policy pressures, and the urgent need to transform healthcare as commercial medical costs climb toward 9%.

From guiding pursuits in artificial intelligence and R&D to scientific marketing and company building, meet Pharm Exec’s new slate of select rising leaders who are helping to shape the next generation of biopharma innovation.

Why pricing pressure, policy volatility and supply-chain risk are pushing drugmakers toward greater cost and portfolio discipline, without losing sight of investment in innovation.

Insights into the "differentiation paradox" from a study of 340 drug launches.

The AstraZeneca-BMS rumors have reframed how the industry thinks about scale, capability, and competitive advantage.

Recent changes at the U.S. Patent and Trademark Office are making it harder to challenge pharmaceutical patents, raising concerns that slower generic and biosimilar competition could undermine efforts to lower drug costs while strengthening protections for brand-name innovators.

Nuvation Bio’s president, CEO, and founder discusses the company’s mission, approach to developing a global strategy, and how it manages its increasing pipeline.

The catalyst for this renewed interest is the USPTO Appeals Review Panel's Ex parte Chamberlain decision and the Federal Circuit decision on appeal.

Novartis filed paperwork in NJ revealing plans to layoff 322 workers in October of this year.

Sanofi Chief Digital Officer Emmanuel Frenehard on scaling AI across a Big Pharma global enterprise and why a strategy of concentrated AI bets — not scattered pilots — can better drive real transformation without losing sight of governance, culture or patients.

The Troutman Pepper Locke senior associate discusses strategies for pharma and biotech companies to implement ahead of the July 31st tariff deadlines.

Healthspan is merging from obscure academic jargon as a potent consumer driver, reshaping how people think about aging and redefining pharma’s role in that process.

Examining the drivers of 340B drug program growth, the impact of vertical integration and contract pharmacies, the ongoing legal and regulatory disputes, and the strategic considerations life sciences companies must navigate in this evolving landscape.

In today's Pharmaceutical Executive Daily, AbbVie announces a $10.9 billion agreement to acquire Apogee Therapeutics, adding a suite of clinical-stage immunology assets to its portfolio, Insilico Medicine enters an AI-powered drug discovery collaboration with SK Biopharmaceuticals valued at up to $2.5 billion to advance neuroimmune treatments in the central nervous system, and Pharmaceutical Executive speaks with Kyle Smith, president and COO of Aprecia Pharmaceuticals, on the real-world benefits and persistent challenges of operating as a fully domestic manufacturer in an era of tariffs and supply chain pressure.

The acquisition will bolster AbbVie’s pipeline, including the addition of monoclonal antibody treatment zumilokibart.

Marketers must navigate a new landscape that sees customers expecting highly-personalized experiences that mirror their experiences with non-health brands.

The driving force behind Lilly’s Medicine Foundry on transforming the discovery-to-production handoff.

Model N Senior Vice President Jesse Mendelsohn explores the hidden costs and realities of PBM-driven drug pricing and the growing challenges manufacturers face in ensuring contract compliance, formulary access and reimbursement accuracy.

Between 2026 and 2030, billions of dollars in revenue will be at risk due to expiring patents and periods of exclusivity.

The Deloitte Consulting partner discusses how GLP-1s are becoming key value drivers and driving R&D focus during a period of market concentration.